

Painful vulval skin conditions

SYDNEY MEDICAL SCHOOL

A/Prof Gayle Fischer OAM M.B.B.S. M.D. F.A.C.D.
Royal North Shore Hospital




THE UNIVERSITY OF
SYDNEY

I have no conflicts of interest to declare



- › ISSVD definition of vulvodynia: “Vulval pain of at least 3 months duration without clear, identifiable cause”
- › Epidemiologic studies claim incidence of 17% and prevalence of 7%.
- › Review of 525 patients with pain only (15% of entire patient population on database)
 - › 61.3% had a dermatosis
 - › 34.5% had a neuromuscular condition
 - › 4.2% had “vulvodynia” as defined above
- › Pain with intercourse only (“provoked”): no difference between neuromuscular and dermatological
- › Harris V, Fischer G, Bradford J 2017 ANZJOG DOI: 10.1111/ajo.12613



- › Vulval disease has a high impact: mean DLQI (range)
- › Psoriasis/Dermatitis 7 (1-23)
- › Lichen sclerosus 7 (1-25)
- › Vulvodynia 9 (1-15)
- › Lichen Planus 11 (1-20)
- › Chronic vulvovaginal candidiasis 15 (1-25)

% with complete response to treatment

- › **Dermatoses: 65.5%**
- › Lichen sclerosus: 92%
- › Lichen planus: 84%
- › Psoriasis: 83%
- › DIV: 82%
- › Chronic candidiasis: 82%
- › Dermatitis: 60%
- › **Neuromuscular: 34.6%**
- › **Vulvodynia: 13.6%**

Caveat: The Skin Condition is not always the cause of the pain

- › Any skin condition can be complicated by secondary neuropathy and or muscle spasm
- › Neuromuscular pain may be the primary complaint and the skin condition a bystander
- › If treating a skin condition adequately does not resolve the pain ask yourself if there is another reason for it

Vulval atopic dermatitis

- › Atopic patients
 - › Dermatitis develops due to irritant exposure
 - › Secret womens' business
 - › Pads
 - › Antifungals
 - › Soap and perfumes
 - › Shaving
 - › Lycra gym gear
 - › Skin tight jeans
 - › G strings
-

- › Environmental modification specific to the vulva
 - › Seek and treat superinfection
 - › Rule out allergy
 - › Initial potent topical steroid until lichenification has resolved
 - › Then emollients, irritant avoidance indefinitely
 - › Weaker topical steroid at first sign of itch
 - › Calcineurin inhibitors are an alternative
-


- › Psoriasis is often non-specific histologically on the vulva
 - › After years of application of topical steroids appearance becomes bland
 - › Usual histo report: spongiosis, lichen simplex
 - › You have to make a clinical diagnosis
 - › Refer to what you know about psoriasis: colour, edge, scale
 - › Natal cleft involvement
 - › Psoriasis on other parts of the skin
-

- › Topical corticosteroids for flares
- › Relying on TCS alone results in tachyphylaxis
- › Tars
- › Calcipotriol
- › UV-B
- › After menopause: low dose acitretin
- › Methotrexate

- › Kapila S, Bradford J, Fischer G: Vulvar Psoriasis in Adults and Children: A clinical audit of 194 cases and review of the literature. 2012 J Lower Gen Tract Dis 16: 4: 364-371
-

- › Prevalence: 3% of female population >50
 - › Significant risk (scarring 50%, malignancy 5%)
 - › Etiology still unknown ? Autoimmune, genetic
 - › Associations: thyroiditis, vitiligo
 - › Large impact on quality of life: Mean DLQI 9 prior to treatment
 - › All age groups including children
-
- › Goldstein AT, Marinoff SC, Christopher K, Srodon M. Prevalence of vulvar lichen sclerosis in a general gynecology practice. J Reprod Med. 2005;50:477-80.
 - › Lee A, Bradford J, Fischer G. Long-term Management of Adult Vulvar Lichen Sclerosis: A Prospective Cohort Study of 507 Women. JAMA Dermatol. 2015;151:1061-7
-





Summary of outcomes


	Compliant %	Partially compliant %	<i>P</i> value
	N= 357 (70.4)	N= 150 (29.6)	
Symptom resolution	93.3	58	<0.001
Dyspareunia resolution	93.7	65.5	<0.001
Scar progression	3.4	40.0	<0.001
SCC or VIN	0	4.7	<0.001

- › Start with a confirmatory biopsy and check thyroid antibodies
- › Induce remission with daily potent TCS (4-6 months)
- › Use preventative treatment → maintain normal skin
- › No “as needed” treatment.
- › Follow up patients: adjust treatment, encourage compliance
- › Titrate TCS to disease severity, response
- › Target outcome: **normal skin colour and texture.**
- › Long-term management with TCS is safe, effective
- › **The course of the disease can be modified by treatment**

- › *Candida* is a normal commensal of gut and vagina
- › Vulvovaginitis from this organism is host dependent
- › Vaginal Candidiasis is estrogen dependent: not seen before menarche and after menopause unless on ERT
- › Maladaptive response to *Candida* in vagina mediated by ER α
- › Polymorphism of TLR 2 may be responsible ? Gain of function



Is the site of pathology the TLR, modified by ER- α ?



- › Biopsy shows spongiosis
 - › A low vaginal swab is only +ve in 75% of cases
 - › pH is normal 4.5
 - › Office microscopy is time consuming, requires skill that many of us don't have and sensitivity is low
 - › Take a careful history
-

- › Have you ever had a +ve swab for Candida?
 - › Do your symptoms cycle?
 - › Do you experience pain with sex?
 - › Do you get thrush from antibiotics
 - › Do you experience soreness (itch is non-specific although common)
 - › Do you have a discharge?
 - › Do you get better with antifungals?
 - › Do you experience post-coital swelling?
 - › Post menopause: are you taking estrogen?
- › Hong et al Vulvovaginal candidiasis as a chronic disease: Diagnostic criteria and definition J Lower Genital Tract Disease 2013

› Group 1

- › Healthy pre-menopausal women mostly
- › Majority onset is in late teens – early 20's
- › Atopic
- › Post menopause on ERT who had Candidiasis before menopause
- › Long term antibiotics
- › Mirena

› Group 2

- › Immunosuppressed
 - › Diabetic
-

- › Long term low-dose oral antifungal
 - › Itraconazole or fluconazole 50-100mg/day for 3 months
 - › In a group of 82 women mean DLQI reduced from 15 to 3.4
 - › Reduce gradually to maintenance dose
 - › Titrate dose to symptoms
 - › Treat secondary dermatitis with weak steroid only
 - › If secondary to ERT, stop it temporarily until recovered then restart under antifungal cover
 - › If secondary to IUD, remove

 - › Nguyen Y, Lee A, Fischer G Australas J Dermatol 2017 58:e176-181
-

- › Group of 201 women: 98% still using antifungal treatment, mainly fluconazole, up to 8 years later
 - › Vulva may always look red even when asymptomatic
 - › Doses vary from prn to daily
 - › Most are on 50mg twice a week
 - › Increase to daily if relapse, antibiotics or travel
 - › Long-term fluconazole is as safe as long-term valacyclovir
 - › Fluconazole does not cause drug induced hepatitis
 - › 95% can tolerate fluconazole long term
 - › Cost is \$30 a month on continuous therapy
-
- › Nguyen Y, Lee A, Fischer G Australas J Dermatol 2017 58: e188-192

- › Uncommon and difficult to diagnose
- › Histopathology not always diagnostic
- › Ulcerative and erosive
- › Vagina is involved
- › Scarring and fusion of vaginal walls
- › Dyspareunia
- › Pain
- › Bloodstained discharge

- › Very complex
 - › Potent topical steroids and pessaries
 - › Topical tacrolimus
 - › Oral prednisone
 - › Oral methotrexate, azathioprine, mycophenolate
 - › Neotigason: not reliable
 - › Adalimumab
 - › Corrective surgery
-



- › Crohn's
- › Aphthous ulcers, Behcet's
- › Recurrent mucosal erythema multiforme
- › Infection: HSV, \$

- › First make a correct diagnosis
- › Acute, recurrent => HSV, Aphthae, Erythema Multiforme, Behcets
- › Chronic: Crohn, \$, some forms of aphthosis, lichen planus

- › Biopsy, serology, PCR

- › HSV: Antiviral therapy, other conditions usually require specialist input

- › Vaginal dryness => dyspareunia
- › Incontinence => pads => dermatoses
- › Make sure you clarify what “dry” means
- › When occurring with other dermatoses, address this as well

- › Diagnosis: pale, flat mucosa,
- › No lubrication on PV, labia minora stick together
- › Can be inflammatory: Petechiae, redness

- › Rx: Oestrogen, lubricant, laser

- › The vulva is part of the skin
- › Certain dermatoses are more common on the vulva
- › The majority of painful vulval conditions are skin conditions
- › Not all ulcers are infections